Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of JMT601 with different chemotherapy regimens in CD20-positive diffuse large B-cell lymphoma
CTR20243768Phase 2Active
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Nov 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of JMT601 in diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma, sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started Nov 2024; status: active.
02
Drugs
JMT601
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphoma
Beyond the preview
Go deeper on CTR20243768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243768.